Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Hub Group,...
-
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of DNOW Inc....
-
Gelatin trick 2026 warning: does the viral gelatin trick recipe work? Pink gelatin trick, ice gelatin trick, and Gelatine Sculpt examined.
-
Washington, D.C., March 28, 2026 (GLOBE NEWSWIRE) -- When Jim Rickards warned that Lehman Brothers was about to implode, almost nobody believed him. Three weeks later, the bank collapsed and took...
-
President Trump's Agenda for Greatness continues in Week 62.
-
New York City, NY, March 28, 2026 (GLOBE NEWSWIRE) -- Many players are curious about online casinos but hesitate when it comes to depositing money on a new site. A no deposit bonus casino...
-
2026 SteelPower performance report covers male enhancement formula details, ingredient research context, pricing, and guarantee disclosures.
-
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...
-
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...
-
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...